Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

Sponsor
Centre Henri Becquerel
Study ID
NCT06879704
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Imaging assessment — OTHER
    The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan

Study Details

The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.

Key Dates

First listed
Mar 17, 2025
Start date
May 28, 2025
Status verified
Dec 2025
Primary completion
Feb 28, 2028
Completion
Nov 28, 2029

Study Design

Enrollment
115 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: PRECISION ARM
    Patient will have four imaging exam : MRI, PET-scan, ultrasound and angio/Mammography

Primary Outcome Measure

concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC). [ Time Frame: two weeks after surgery ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsOncology trialsBreast oncology trialsWomen's health trials

Related Studies